Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
02 June 1995Website:
http://www.resmed.comNext earnings report:
24 January 2025Last dividends:
07 November 2024Next dividends:
N/APrice
after hours | Sat, 16 Nov 2024 00:35:42 GMTAnalysts recommendations
Institutional Ownership
Included in screeners
RMD Latest News
Strong sales of masks and devices are a positive sign for ResMed. However, the growing amount of debt is a cause for concern.
ResMed (RMD) has strong growth characteristics that may enable it to significantly exceed market performance.
No matter if you invest in value, growth, or momentum, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.
Mick Farrell, the CEO of ResMed (RMD), appears on Morning Trade Live to talk about the company's recent success in earnings. ResMed mainly specializes in treating sleep apnea and chronic obstructive pulmonary disease (COPD).
On Thursday, ResMed Inc (RMD) announced its adjusted earnings per share (EPS) for the first quarter, which was $2.20. This represents a 34% increase compared to the same period last year and is higher than the expected EPS of $2.04.
RMD's impressive results for the first quarter of fiscal 2025 show the continued progress and effective performance in every part of its operations.
ResMed Inc. (NYSE:RMD) will hold its Q1 2025 Earnings Conference Call on October 24, 2024, at 4:30 PM ET. The call will feature key company participants, including Amy Wakeham, Michael Farrell, and Brett Sandercock, along with various conference call participants from different financial institutions. The operator, Kevin, will guide the call.
The main figures for ResMed (RMD) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be helpful to look at some of its important metrics in relation to Wall Street predictions and the results from the same period last year.
ResMed (RMD) reported quarterly earnings of $2.20 per share, which is higher than the Zacks Consensus Estimate of $2.03 per share. This is an increase compared to earnings of $1.64 per share from the same period last year.
On Thursday, ResMed exceeded Wall Street's expectations for its quarterly profit, thanks to high demand for its sleep apnea treatment devices.
What type of business is ResMed?
ResMed Inc. is one of the world leaders in the development, manufacturing, and marketing of medical devices and cloud software solutions for the diagnosis, treatment, and management of respiratory disorders. The company's portfolio includes a range of innovative products for a wide spectrum of respiratory diseases, including technologies used in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in hospitals and homes, headgear and other accessories, dental devices, portable oxygen concentrators, as well as cloud software information solutions for managing patient outcomes and business processes for clients and suppliers. ResMed Inc. was founded in 1989 with headquarters in San Diego, California.
What sector is ResMed in?
ResMed is in the Healthcare sector
What industry is ResMed in?
ResMed is in the Medical Instruments & Supplies industry
What country is ResMed from?
ResMed is headquartered in United States
When did ResMed go public?
ResMed initial public offering (IPO) was on 02 June 1995
What is ResMed website?
https://www.resmed.com
Is ResMed in the S&P 500?
Yes, ResMed is included in the S&P 500 index
Is ResMed in the NASDAQ 100?
No, ResMed is not included in the NASDAQ 100 index
Is ResMed in the Dow Jones?
No, ResMed is not included in the Dow Jones index
When was ResMed the previous earnings report?
No data
When does ResMed earnings report?
The next expected earnings date for ResMed is 24 January 2025